Skip to content

Insider · CIK 0001567045

Kenneth Galbraith

ceochairofficerdirector

Files at ZYME (Zymeworks Inc.). First filing Jan 6, 2025, latest Jan 12, 2026.

Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 4
$0 bought, $4.2M sold

Where the trades landed

Last year at the company this insider has traded most, with each buy and sell on the bar it happened.

ZYME: Zymeworks Inc.

ZYMEOct 9, 2026 · close 25.79

Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™

Signals

This insider’s open-market buys and sells, scored.

ScoreCompanyValueHoldingsPrice contextFiled
44Moderate
ZYMEsell 2
Zymeworks Inc.
$690k
30,424 shares
-12%+145% from low-16% from high
53Moderate
ZYMEsell 2
Zymeworks Inc.
$1.4M
54,343 shares
-30%+170% from low-8% from high
45Moderate
ZYMEsell
Zymeworks Inc.
$1.3M
47,528 shares
-26%+193% from low0% from high
53Moderate
ZYMEsell
Zymeworks Inc.
$855k
57,291 shares
-80%+20% from low-17% from high

Transactions

Every row this insider has filed, newest first.

DateCompanyTransactionSharesPriceValueHoldings afterFiled
Jan 12, 2026ZYME
Zymeworks Inc.
MOption exercise
Common Stock
+64,000$0.00$0257,266Jan 12, 2026
Jan 12, 2026ZYME
Zymeworks Inc.
SOpen-market sale
Common Stock
-30,424$22.67$690k226,842Jan 12, 2026
Jan 12, 2026ZYME
Zymeworks Inc.
MOption exercise
Restricted Stock Unitderivative
-64,000$0.00$0128,000Jan 12, 2026
Jan 12, 2026ZYME
Zymeworks Inc.
AGrant or award
Stock Option (Right to Buy)derivative
+216,000$0.00$0216,000Jan 12, 2026
Jan 12, 2026ZYME
Zymeworks Inc.
AGrant or award
Restricted Stock Unitderivative
+144,000$0.00$0144,000Jan 12, 2026
Jan 12, 2026ZYME
Zymeworks Inc.
AGrant or award
Performance Stock Unitderivative
+222,000$0.00$0222,000Jan 12, 2026
Jan 5, 2026ZYME
Zymeworks Inc.
MOption exercise
Common Stock
+47,668$0.00$0180,943Jan 5, 2026
Jan 5, 2026ZYME
Zymeworks Inc.
SOpen-market sale
Common Stock
-22,657$25.10$569k158,286Jan 5, 2026
Jan 5, 2026ZYME
Zymeworks Inc.
MOption exercise
Common Stock
+66,666$0.00$0224,952Jan 5, 2026
Jan 5, 2026ZYME
Zymeworks Inc.
SOpen-market sale
Common Stock
-31,686$25.10$795k193,266Jan 5, 2026
Jan 5, 2026ZYME
Zymeworks Inc.
MOption exercise
Restricted Stock Unitderivative
-47,668$0.00$00Jan 5, 2026
Jan 5, 2026ZYME
Zymeworks Inc.
MOption exercise
Restricted Stock Unitderivative
-66,666$0.00$066,668Jan 5, 2026
Dec 22, 2025ZYME
Zymeworks Inc.
MOption exercise
Common Stock
+100,000$0.00$0180,803Dec 22, 2025
Dec 22, 2025ZYME
Zymeworks Inc.
SOpen-market sale
Common Stock
-47,528$27.02$1.3M133,275Dec 22, 2025
Dec 22, 2025ZYME
Zymeworks Inc.
MOption exercise
Restricted Stock Unitderivative
-100,000$0.00$00Dec 22, 2025
Jan 10, 2025ZYME
Zymeworks Inc.
AGrant or award
Stock Option (Right to Buy)derivative
+288,000$0.00$0288,000Jan 10, 2025
Jan 10, 2025ZYME
Zymeworks Inc.
AGrant or award
Restricted Stock Unitderivative
+192,000$0.00$0192,000Jan 10, 2025
Jan 6, 2025ZYME
Zymeworks Inc.
MOption exercise
Common Stock
+47,666$0.00$071,428Jan 6, 2025
Jan 6, 2025ZYME
Zymeworks Inc.
SOpen-market sale
Common Stock
-23,885$14.92$356k47,543Jan 6, 2025
Jan 6, 2025ZYME
Zymeworks Inc.
MOption exercise
Common Stock
+66,666$0.00$0114,209Jan 6, 2025
Jan 6, 2025ZYME
Zymeworks Inc.
SOpen-market sale
Common Stock
-33,406$14.92$499k80,803Jan 6, 2025
Jan 6, 2025ZYME
Zymeworks Inc.
MOption exercise
Restricted Stock Unitderivative
-47,666$0.00$047,668Jan 6, 2025
Jan 6, 2025ZYME
Zymeworks Inc.
MOption exercise
Restricted Stock Unitderivative
-66,666$0.00$0133,334Jan 6, 2025

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.

Kenneth Galbraith: insider trades and track record | InsiderTell